# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
TD Cowen analyst Boris Peaker downgrades GlycoMimetics (NASDAQ:GLYC) from Buy to Hold.
- SEC Filing
On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305 thousand shares in the company.
- SEC Filing
HC Wainwright & Co. analyst Edward White reiterates GlycoMimetics (NASDAQ:GLYC) with a Neutral.
Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinica...